SEC Form 4 · accession 0001493152-26-035962
Inhibitor Therapeutics, Inc. · INTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Ronald E Osman
Director · 10% Owner
Period of report
May 4, 2026
Accepted (ET)
Aug 4, 2026 · 1:33 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001042418
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 4, 2026 | A | 50,000 | $0.00 | A | 23,614,985 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan, subject to shareholder approval.
- F2These shares represent 100,000 shares owned by Mr. Osman and remaining number of shares of common stock held by The Ronald E. Osman Trust III. Mr. Osman is the sole trustee of the Ronald E. Osman Trust III.